Description  Claims  Drawing  Cited references 

WO2016130917A   [0003] 
US3773919A   [0080] 

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses   [0003] 
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes   [0003] 
Perspectives in the treatment of pancreatic adenocarcinoma   [0003] 
Inhibition of Ras for cancer treatment: the search continues   [0003] 
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance   [0003] 
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer   [0003] 
Nature   [0003] 
Mol.Cell. Therapeutics   [0003] 
Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer   [0018] 
Myofibroblasts are responsible for the desmoplastic reaction surrounding human pancreatic carcinomas   [0018] 
Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling   [0018] 
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma   [0018] 
Coffee EM, Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models   [0018] 
1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites   [0018] 
STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis   [0018] 
Pancreatic cancer   [0019] 
Pancreatic cancer-associated stroma production   [0019] 
Complex role for the immune system in initiation and progression of pancreatic cancer   [0019] 
The immune network in pancreatic cancer development and progression   [0019] 
Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival   [0019] 
The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma   [0019] 
Target therapies in pancreatic carcinoma   [0019] 
Metastatic pancreatic cancer: Is there a light at the end of the tunnel?   [0019] 
Understanding metastasis in pancreatic cancer: a call for new clinical approaches   [0019] 
Inflammatory networks and immune surveillance of pancreatic carcinoma   [0019] 
Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy   [0019] 
Distribution and clinical significance of tumour-associated macrophages in pancreatic ductal adenocarcinoma: a retrospective analysis in China   [0019] 
Tumor-associated macrophages: from mechanisms to therapy   [0019] 
Therapeutic vaccines for cancer: an overview of clinical trials   [0019] 
Combination immunotherapy approaches   [0019] 
Gaudernack G, Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras   [0019] 
Understanding local macrophage phenotypes in disease: modulating macrophage function to treat cancer   [0019] 
Adv. Enzyme Regul.   [0027] 
New Avenues in Developmental Cancer Chemotherapy   [0027] 
Molecular Systems Biology   [0027] 
Remington's Pharmaceutical Sciences   [0076] 
Systematic discovery of multicomponent therapeutics   [0102] 
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen   [0103] 
Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response   [0107] 
R Development Core Team   [0108] 
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer   [0120] 
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells   [0120] 
STAT3 mediates resistance to MEK inhibitor through microRNA miR-17   [0120]